Obermeyer Wood Investment Counsel Lllp decreased its stake in shares of Celgene Co. (NASDAQ:CELG) by 14.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 248,369 shares of the biopharmaceutical company’s stock after selling 40,349 shares during the period. Celgene makes up 2.2% of Obermeyer Wood Investment Counsel Lllp’s investment portfolio, making the stock its 24th largest holding. Obermeyer Wood Investment Counsel Lllp’s holdings in Celgene were worth $23,431,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Investors Research Corp bought a new stake in Celgene during the first quarter worth about $28,000. Creative Financial Designs Inc. ADV boosted its stake in Celgene by 1,968.8% during the first quarter. Creative Financial Designs Inc. ADV now owns 331 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 315 shares in the last quarter. Bruderman Asset Management LLC bought a new stake in Celgene during the fourth quarter worth about $25,000. Murphy Pohlad Asset Management LLC bought a new stake in Celgene during the fourth quarter worth about $25,000. Finally, Athena Capital Advisors LLC bought a new stake in Celgene during the fourth quarter worth about $27,000. 71.71% of the stock is currently owned by hedge funds and other institutional investors.

CELG opened at $94.15 on Thursday. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $97.07. The company has a market cap of $66.40 billion, a PE ratio of 12.37, a P/E/G ratio of 0.43 and a beta of 1.68.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. During the same period in the previous year, the company earned $2.05 earnings per share. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. As a group, research analysts predict that Celgene Co. will post 9.85 EPS for the current fiscal year.

Several equities research analysts recently commented on the stock. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. Barclays cut shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a report on Friday, May 3rd. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Mizuho set a $103.00 target price on shares of Celgene and gave the stock a “buy” rating in a report on Friday, April 5th. Finally, Cantor Fitzgerald cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 target price for the company. in a report on Friday, April 5th. Twenty equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $95.96.

TRADEMARK VIOLATION WARNING: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://theolympiareport.com/2019/05/16/obermeyer-wood-investment-counsel-lllp-cuts-stake-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What are defining characteristics of a correction?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.